AstraZeneca Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 4/6

AstraZeneca kazançlarla iyi bir şekilde karşılanan, 2.32% cari getiriye sahip, temettü ödeyen bir şirkettir.

Anahtar bilgiler

2.3%

Temettü verimi

0.02%

Geri Alım Getirisi

Toplam Hissedar Getirisi	2.3%
Gelecekteki Temettü Verimi	2.7%
Temettü Büyümesi	-8.6%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	UK£2.336
Ödeme oranı	71%

Son temettü ve geri alım güncellemeleri

AstraZeneca (LON:AZN) Has Announced A Dividend Of $0.776

Jul 30

Recent updates

AstraZeneca PLC's (LON:AZN) Price In Tune With Earnings

Oct 19

AstraZeneca (LON:AZN) Has Announced A Dividend Of $0.776

Jul 30

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: AZN şirketinin temettü ödemeleri son 10 yıldır dalgalı seyretti.

Büyüyen Temettü: AZN şirketinin temettü ödemeleri son 10 yıldır artış göstermektedir.

Piyasaya Karşı Temettü Getirisi

AstraZeneca Piyasaya Karşı Temettü Getirisi

AZN temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (AZN)	2.3%
Pazarın Alt %25'i (GB)	2.1%
Pazarın En İyi %25'i (GB)	5.9%
Sektör Ortalaması (Pharmaceuticals)	2.6%
Analist tahmini (AZN) (3 yıla kadar)	2.7%

Önemli Temettü: AZN 'in temettüsü ( 2.32% ), UK piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 2.14% ) daha yüksektir.

Yüksek Temettü: AZN 'in temettüsü ( 2.32% ), UK piyasasındaki temettü ödeyenlerin en üst %25'ine ( 5.91% ) kıyasla düşüktür.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Makul ödeme oranı ( 70.9% ) ile AZN 'un temettü ödemeleri kazançlarla karşılanmaktadır.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Makul nakit ödeme oranı ( 66.5% ) ile AZN 'un temettü ödemeleri nakit akışları ile karşılanmaktadır.

AstraZeneca Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 4/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

AstraZeneca (LON:AZN) Has Announced A Dividend Of $0.776

Recent updates

CEO & Executive Director recently bought UK£2.0m worth of stock

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Amgen and AstraZeneca Announce Positive Top-Line Results from the Phase 3 WayPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps

Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Astrazeneca plc Announces Astrazeneca and Ionis' Wainzua (Eplontersen) Recommendation for Approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union

AstraZeneca PLC's (LON:AZN) Price In Tune With Earnings

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

Astrazeneca’S CALQUENCE® (acalabrutinib) Receives Priority Review in the US for Patients with Untreated Mantle Cell Lymphoma

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Cas Datifan in Combination with Volrustomig in Renal Cell Carcinoma

Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US

Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy

Astrazeneca PLC Tagrisso Receives US Approval in Unresectable Stage III EGFR-Mutated Lung Cancer Lung Cancer

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer

AstraZeneca PLC’s FluMist Receives Approval for Self-Administration in the US

AstraZeneca PLC's Fasenra Approves in the US for Eosinophilic Granulomatosis with Polyangiitis

AstraZeneca Announces Positive Results from the Niagara Phase III Trial

Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases

Astrazeneca Presents Interim Results from the Randomized NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Present At the WCLC 2024

Astrazeneca's Imfinzi Receives Approval in US for the Treatment of Resectable Non-Small Cell Lung Cancer Before and After Surgery

Astrazeneca's Supplemental Biologics License Application for Imfinzi (Durvalumab) Granted Priority Review and Breakthrough Therapy Designation for Patients with Limited-Stage Small Cell Lung Cancer in the US

Astrazeneca Announces Positive High-Level Results from an Interim Analysis of the Amplify Phase III Trial

AstraZeneca (LON:AZN) Has Announced A Dividend Of $0.776

Astrazeneca Announces Positive High-Level Results from an Interim Analysis of the Amplify Phase III Trial

First half dividend of UK£0.78 announced

FDA Advisory Committee Reviewes Astrazeneca's Imfinzi for Treatment of Resectable Non-Small Cell Lung Cancer Based on Aegean Phase III Trial Results

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin